A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Full story
Read the full story at CNBC ↗
Continue reading this story on CNBC, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
